Log in with your email address username.


[Comment] No small task: therapeutic targeting of Lp(a) for cardiovascular disease

Despite primary and secondary prevention efforts, ischaemic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Genome-wide association studies (GWAS) over the past decade have revealed dozens of loci associated with increased risk of coronary artery disease that could serve as potential new targets for therapy. Among them are genes that affect LDL metabolism such as LPA, which encodes for the glycoprotein apolipoprotein(a), a principle component of the LDL-like particle lipoprotein(a) (Lp[a]).